Spruce Biosciences, Inc. (SPRB) Stock Analysis
A live, multi-source view of Spruce Biosciences, Inc. (SPRB): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Sector: Healthcare · Industry: Biotechnology · United States · 22 employees · sprucebio.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Spruce Biosciences, Inc. (SPRB) had a market capitalization of $166.5M (forward 7.1) and a beta of 3.36; the shares traded in a 52-week range of $7.26 – $240.00 (541.2% over the year).
- Market cap
- $166.5M
- Enterprise value
- $77.9M
- Forward P/E
- 7.1
- Price / book
- 1.90
- EPS (trailing)
- $-38.43
- EPS (forward)
- $8.17
- Payout ratio
- 0.0%
- 52-week range
- $7.26 – $240.00
- 52-week change
- 541.2%
- Beta
- 3.36
- Average volume
- 72,696
- Shares outstanding
- 2.9M
- Short % of float
- 14.16%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Spruce Biosciences, Inc. (SPRB) last closed at $54.35 (the last completed close before that scan).
Technicals at the scan: RSI 49 (neutral territory), price -3.9% versus its 20-day average, 20-day versus 50-day average spread +12.2%, MACD histogram -0.63.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 75/100.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for SPRB in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
SPRB has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Spruce Biosciences, Inc. (SPRB) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell SPRB.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.